• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B3 filed by Spectral AI Inc.

    12/4/24 4:06:53 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care
    Get the next $MDAI alert in real time by email
    424B3 1 ea0223696-424b3_spectral.htm PROSPECTUS SUPPLEMENT

    Filed Pursuant to Rule 424(b)(3)

    Registration No. 333-283369

     

    PROSPECTUS SUPPLEMENT NO. 1

    (to Prospectus dated December 2, 2024)

     

    SPECTRAL AI, INC.

     

    UP TO 1,000,000 SHARES OF COMMON STOCK

     

    This prospectus supplement is being filed solely to update the information contained in the table in the “Selling Securityholders” section of the prospectus dated December 2, 2024 (the “Prospectus”) to reflect certain transfers described herein.

     

    The Prospectus and this prospectus supplement relate to the offer and sale from time to time by the selling securityholders named in this prospectus or their permitted transferees (the “Selling Securityholders”) of (i) up to 1,000,000 shares of Common Stock issuable upon conversion of the Promissory Note. We will not receive any proceeds from the sale of shares of Common Stock by the Selling Securityholders pursuant to this prospectus.

     

    The Selling Securityholders may offer and sell the securities covered by the Prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Securityholders may sell the shares in the section entitled “Plan of Distribution.”

     

    Our shares of Common Stock are listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “MDAI.” On December 3, 2024, the closing price of our Common Stock was $2.20 per share.

     

    This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

     

    Investing in our Common Stock involves risks that are described in the “Risk Factors” section beginning on page 4 of the Prospectus and under similar headings in any further amendments or supplements to the Prospectus.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

     

    The date of this prospectus supplement is December 4, 2024.

     

     

    SELLING SECURITYHOLDERS

     

    The following information is provided as of December 3, 2024 to update the “Selling Securityholders” section of the Prospectus to reflect the purchase of a portion of the Promissory Note by Eleven Ventures LLC.

     

    Where the name of a Selling Securityholder identified in the table below also appears in the table in the Prospectus, the information set forth in the table below regarding that Selling Securityholder supersedes and replaces the information regarding such Selling Securityholder in the Prospectus. Information regarding the Selling Securityholders listed in the table below, including the number of shares of Common Stock beneficially owned by them, is based on information provided by such Selling Securityholders as of the date of this prospectus supplement.

     

    Information about the Selling Securityholders, including those listed below, may change over time. Since the effectiveness of the Registration Statement on Form S-1 of which the Prospectus is a part, Selling Securityholders have sold or otherwise transferred their securities registered thereunder. This prospectus supplement does not provide any updates with respect to any such exercises, sales or transfers, except for those expressly referred to in the immediately preceding paragraph.

     

        Shares of Common Stock  
    Name   Number
    Beneficially
    Owned
    Prior to
    Offering
        Percent
    Beneficially
    Owned Prior to
    Offering
        Number
    Registered
    for Sale
    Hereby
        Number
    Beneficially
    Owned
    After
    Offering
     
    IP Protocol, LLC (1)     778,394       4.19%       778,394           —  
    Eleven Ventures LLC(2)     221,606       1.19%       221,606       —  
    Total     1,000,000               1,000,000       —  

     

    (1)   IP Protocol, LLC is the direct holder of these shares. Peter Benz is the managing member and has voting and investment power over the reported shares offered hereby. The address of the selling stockholder is 4843 Three Oaks Blvd., Sarasota, FL 34233.
       
    (2) Eleven Ventures LLC is managed by Eleven Managers LLC. Hartley Wasko is the sole manager of Eleven Managers LLC. Accordingly, Eleven Managers LLC and Hartley Wasko are each deemed to have beneficial ownership of Eleven Ventures LLC. The business address of Eleven Ventures LLC is 463 Adams Street, Denver, CO 80206.  

     

     

    Get the next $MDAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDAI

    DatePrice TargetRatingAnalyst
    1/23/2024$4.00Buy
    BTIG Research
    More analyst ratings

    $MDAI
    SEC Filings

    View All

    Spectral AI Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Spectral AI, Inc. (0001833498) (Filer)

    2/10/26 4:01:26 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Spectral AI, Inc. (0001833498) (Filer)

    2/3/26 4:01:39 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Inc. filed SEC Form 8-K: Leadership Update

    8-K - Spectral AI, Inc. (0001833498) (Filer)

    1/6/26 4:01:53 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dimaio John Michael was granted 11,700 shares, increasing direct ownership by 0.47% to 2,503,608 units (SEC Form 4)

    4 - Spectral AI, Inc. (0001833498) (Issuer)

    6/10/25 4:01:14 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Director Mellish Martin C.B. was granted 5,000 shares, increasing direct ownership by 26% to 24,398 units (SEC Form 4)

    4 - Spectral AI, Inc. (0001833498) (Issuer)

    6/6/25 4:00:24 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Director Cotton Richard John was granted 9,699 shares, increasing direct ownership by 17% to 66,927 units (SEC Form 4)

    4 - Spectral AI, Inc. (0001833498) (Issuer)

    5/1/25 4:00:30 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spectral AI Names Vincent S. Capone as Chief Executive Officer

    DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026. The appointment of Mr. Capone, who currently serves as the Company's Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System. "Vince brings a unique set

    2/10/26 8:30:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI to Participate in National Burn Awareness Week 2026 February 1–7, 2026

    DALLAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will join the American Burn Association (ABA) to promote practical, life-saving burn prevention strategies for workplaces of all types during this year's National Burn Awareness Week. In support of this annual event, Spectral AI will host a series of internal activities to engage employees, including inspiring messages from leadership, personal stories from biomedical engineers highlighting the importance of innovation in burn

    2/2/26 8:30:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Announces 2025 Third Quarter Financial Results

    Q3 Overview Research & Development Revenue of $3.8 Million; $15.6 Million in YTD Revenue for 2025Strong Cash position of $10.5 Million and progress toward FDA De Novo submission DALLAS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its ongoing business activities. The Company maintained a strong cash position of $10.5 million, recorded $3.8 million in research and development revenue, and continue

    11/11/25 4:00:00 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Dimaio John Michael bought $10,320 worth of shares (6,000 units at $1.72), increasing direct ownership by 0.40% to 2,491,908 units (SEC Form 4)

    4 - Spectral AI, Inc. (0001833498) (Issuer)

    5/14/24 11:17:43 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Spectral AI with a new price target

    BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00

    1/23/24 7:24:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Leadership Updates

    Live Leadership Updates

    View All

    Spectral AI Names Vincent S. Capone as Chief Executive Officer

    DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026. The appointment of Mr. Capone, who currently serves as the Company's Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System. "Vince brings a unique set

    2/10/26 8:30:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

    DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company's Chief Operating Officer ("COO"). Micek's promotion reflects his role change from Interim COO of the Company since May, 2024 "Stan has demonstrated exceptional leadership, operational insight, and a deep understanding of our business during his time as interim COO," said Dr. J. Michael DiMaio, M.D., Chairman of the Company's Board of Directors. "His efforts leading our Research and Devel

    5/30/25 8:00:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders

    DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company's total shares outstanding were represented at the meeting, either in person or by proxy. Both of the proposals set forth by the Company were approved by its stockholders. The voting results are detailed below. Six directors were elected to serve on the Company's Board of Directors until the next Annual Me

    5/29/25 8:00:00 AM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Financials

    Live finance-specific insights

    View All

    Spectral AI Announces 2025 Third Quarter Financial Results

    Q3 Overview Research & Development Revenue of $3.8 Million; $15.6 Million in YTD Revenue for 2025Strong Cash position of $10.5 Million and progress toward FDA De Novo submission DALLAS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its ongoing business activities. The Company maintained a strong cash position of $10.5 million, recorded $3.8 million in research and development revenue, and continue

    11/11/25 4:00:00 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Schedules 2025 Third Quarter Financial Results and Conference Call

    DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2025 on Tuesday, November 11, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 – U.S.412-317-1837 – International A simultaneous webcast of the call may be accessed online fr

    10/28/25 4:00:00 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    Spectral AI Announces 2025 Second Quarter Financial Results

    Q2 Overview Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 MillionStrong Cash position of $10.5 MillionSubmission of De Novo application to FDA completed in Second Quarter of 2025 DALLAS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2025 and provided an update on its ongoing business activities. "We are pleased with the results of our second quarter of 2025 especially with our ab

    8/12/25 4:00:00 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    $MDAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Spectral AI Inc.

    SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)

    11/14/24 4:09:49 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Spectral AI Inc. (Amendment)

    SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)

    4/19/24 6:49:51 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Spectral AI Inc. (Amendment)

    SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)

    2/27/24 2:07:28 PM ET
    $MDAI
    Medical/Dental Instruments
    Health Care